Cargando…

Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers

The discovery of reprogramming and generation of human-induced pluripotent stem cells (iPSCs) has revolutionized the field of regenerative medicine and opened new opportunities in cell replacement therapies. While generation of iPSCs represents a significant breakthrough, the clinical relevance of i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shafa, Mehdi, Yang, Fan, Fellner, Thomas, Rao, Mahendra S., Baghbaderani, Behnam Ahmadian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862873/ https://www.ncbi.nlm.nih.gov/pubmed/29600249 http://dx.doi.org/10.3389/fmed.2018.00069

Ejemplares similares

Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
por: Baghbaderani, Behnam Ahmadian, et al.
Publicado: (2016)

cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications
por: Baghbaderani, Behnam Ahmadian, et al.
Publicado: (2015)

Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes
por: Shafa, Mehdi, et al.
Publicado: (2019)

Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells
por: Shafa, Mehdi, et al.
Publicado: (2019)

Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions
por: Suresh Babu, Sahana, et al.
Publicado: (2023)

Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell‐Derived Hepatocytes for Cell‐Based Therapy
por: Blackford, Samuel J.I., et al.
Publicado: (2018)

Development of genetic quality tests for good manufacturing practice-compliant induced pluripotent stem cells and their derivatives
por: Jo, Hye-Yeong, et al.
Publicado: (2020)

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production
por: Oeller, Michaela, et al.
Publicado: (2021)

Generation of Transplantable Retinal Photoreceptors from a Current Good Manufacturing Practice‐Manufactured Human Induced Pluripotent Stem Cell Line
por: Zhu, Jie, et al.
Publicado: (2017)

A Newly Defined and Xeno-Free Culture Medium Supports Every-Other-Day Medium Replacement in the Generation and Long-Term Cultivation of Human Pluripotent Stem Cells
por: Ahmadian Baghbaderani, Behnam, et al.
Publicado: (2016)

Manufacturing Cells for Clinical Use
por: Weiss, Mark L., et al.
Publicado: (2016)

Good manufacturing practice-compliant isolation and culture of human umbilical cord blood-derived mesenchymal stem cells
por: Pham, Phuc Van, et al.
Publicado: (2014)

A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions
por: Mareschi, Katia, et al.
Publicado: (2022)

Cell-based medicinal products and the development of GMP-compliant processes and manufacturing
por: Romagnoli, Luca, et al.
Publicado: (2011)

Distributed automated manufacturing of pluripotent stem cell products
por: Shariatzadeh, Maryam, et al.
Publicado: (2019)

The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices
por: Fabio, Petrelli, et al.
Publicado: (2019)

Food and Drink - Good Manufacturing Practice
por: Manning, Louise
Publicado: (2018)

Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents
por: Sanz-Nogués, Clara, et al.
Publicado: (2021)

End-to-End Platform for Human Pluripotent Stem Cell Manufacturing
por: Pandey, Puspa R., et al.
Publicado: (2019)

Considering Cell Therapy Product “Good Manufacturing Practice” Status
por: Bedford, Patrick, et al.
Publicado: (2018)

Host Cell Proteins in Biologics Manufacturing: The Good, the Bad, and the Ugly
por: Kornecki, Martin, et al.
Publicado: (2017)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
por: Wiesinger, Manuel, et al.
Publicado: (2017)

Good manufacturing practices for pharmaceuticals : a plan for total quality control
por: Willig, Sidney H., 1919-
Publicado: (1997)

Safety Profile of Good Manufacturing Practice Manufactured Interferon γ‐Primed Mesenchymal Stem/Stromal Cells for Clinical Trials
por: Guess, Adam J., et al.
Publicado: (2017)

Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies
por: Kim, Jung-Hyun, et al.
Publicado: (2022)

Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production
por: Camilleri, Emily T., et al.
Publicado: (2016)

Impact of current good manufacturing practices and emission regulations and guidances on the discharge of pharmaceutical chemicals into the environment from manufacturing, use, and disposal.
por: Velagaleti, Ranga, et al.
Publicado: (2002)

Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice
por: Gándara, Carolina, et al.
Publicado: (2018)

Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
por: Shankar, Keerthana, et al.
Publicado: (2020)

Challenges and Solutions for Commercial Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products
por: Lee, Brian, et al.
Publicado: (2020)

Good manufacturing practices for medicinal products for human use
por: Gouveia, Bruno G., et al.
Publicado: (2015)

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy
por: Fernández, Lucía, et al.
Publicado: (2019)

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18
por: Glienke, Wolfgang, et al.
Publicado: (2022)

Xeno-free protocol for GMP-compliant manufacturing of human fetal pancreas-derived mesenchymal stem cells
por: Jabbarpour, Zahra, et al.
Publicado: (2022)

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells
por: Tischer, Sabine, et al.
Publicado: (2014)

Inter-center comparison of good manufacturing practices-compliant stromal vascular fraction and proposal for release acceptance criteria: a review of 364 productions
por: François, Pauline, et al.
Publicado: (2021)

The isochromosome 20q abnormality of pluripotent cells interrupts germ layer differentiation
por: Vitillo, Loriana, et al.
Publicado: (2023)

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
por: Vickers, Mark A, et al.
Publicado: (2014)

Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source
por: Laroye, Caroline, et al.
Publicado: (2019)

Heparin Promotes Cardiac Differentiation of Human Pluripotent Stem Cells in Chemically Defined Albumin‐Free Medium, Enabling Consistent Manufacture of Cardiomyocytes
por: Lin, Yongshun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5d6rnlvmmnk0fkrfbgqpio8979